Horst Flotow

After obtaining his PhD from Flinders University of South Australia and postdoctoral stints at IUPUI Medical School (Indiana University, US) and the Friedrich Miescher Institute in Basel, Switzerland, Horst Flotow joined the pharmaceutical industry in 1993, at Roche in the UK, working with protein kinases involved in T-cell signal transduction. Moving on to Singapore in 1999, he joined the Centre for Natural Product Research, which then became MerLion Pharmaceuticals. As a Director of High-Throughput Screening (HTS) at Merlion, Horst was responsible for developing and running HTS assays for drug discovery in a variety of therapeutic areas. Following a brief stint as a Research Consultant at Lilly Systems Biology (LSB) he moved to the Experimental Therapeutics Centre, when it was established in 2007 as the founding Group Leader for the HTS group and the Head of the Singapore Screening Centre. In 2015 he moved to lead Hit Discovery Constance in Germany. Since 2020 Horst has been the Senior director of Business Development and Research Collaborations at HitGen Inc., a provider of DNA-encoded compound library technology and services.